Blog

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL – OncLive


YouTube

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL
OncLive
Aaron C. Logan, MD, PhD: It's definitely exciting, but I think this particular generation of CAR T cells does carry a lot of toxicity, and it requires extreme expertise to administer this therapy to patients. I don't think that 10 years from now, this
CAR T-Cell Therapy in ALL: Formidible Challenges RemainCancer Network



all 7 news articles »

2018-04-04 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.